Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Health, Population and Nutrition

• Publication date

  2004-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3329/JHPN.V22I3.274PMID 15609780
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statistical considerations for vaccine immunogenicity trials. Part 1: Introduction and bioassay design and analysis.

  2005cited by this paper
• Statistical considerations for vaccine immunogenicity trials. Part 2: Noninferiority and other statistical approaches to vaccine evaluation.

  2005cited by this paper
• Case-control studies of the effectiveness of vaccines: validity and assessment of potential bias

  2004cited by this paper
• Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis

  2003cited by this paper
• Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries.

  2003cited by this paper
• Effectiveness of meningococcal C conjugate vaccine in teenagers in England.

  2003cited by this paper
• Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers

  2002cited by this paper
• Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.

  2002cited by this paper
• Vaccines for the prevention of meningococcal disease in children.

  2002cited by this paper
• Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults.

  2002cited by this paper
• Meningococcal meningitis in Africa.

  2002cited by this paper
• Evaluating the immune response to combination vaccines.

  2001cited by this paper
• Product development plan for new vaccine technologies.

  2001cited by this paper
• Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.

  2001cited by this paper
• Meningococcal disease.

  2001cited by this paper
• Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England

  2001cited by this paper
• Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of Protection

  2001cited by this paper
• Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger

  2000cited by this paper
• Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 2: Practical Issues and Specific Cases

  2000cited by this paper
• Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues

  2000cited by this paper
• Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines.

  2000cited by this paper
• The world health report 2000 - Health systems: improving performance

  2000cited by this paper
• Manson Lecture. Meningococcal meningitis in Africa.

  1999cited by this paper
• Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood.

  1999cited by this paper
• Meningococcal conjugate vaccines: new opportunities and new challenges.

  1999cited by this paper
• Age-Dependent Neisseria meningitidis Serogroup C Class-Specific Antibody Concentrations and Bactericidal Titers in Sera from Young Children from Montana Immunized with a Licensed Polysaccharide Vaccine

  1998cited by this paper
• Study designs for evaluating different efficacy and effectiveness aspects of vaccines.

  1997cited by this paper
• Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine.

  1997cited by this paper
• The contribution of the case-control approach to vaccine evaluation: Pneumococcal and Haemophilus influenzae type B PRP vaccines.

  1996cited by this paper
• Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants.

  1996cited by this paper
• Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children.

  1996cited by this paper
• A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants.

  1995cited by this paper
• Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C.

  1992cited by this paper
• Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines.

  1992cited by this paper
• Haemophilus influenzae type B conjugate vaccines.

  1990cited by this paper
• Trends in mortality in children hospitalized with meningococcal infections, 1957 to 1987.

  1989cited by this paper
• Meningococcal carriage, meningococcal disease and vaccination.

  1988cited by this paper
• Assessing vaccine efficacy in the field. Further observations.

  1988cited by this paper
• Group A meningococcal carriage in travelers returning from Saudi Arabia.

  1988cited by this paper
• Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine.

  1985cited by this paper
• Field evaluation of vaccine efficacy.

  1985cited by this paper
• Meningococcal disease and season in sub-Saharan Africa.

  1985cited by this paper
• Selective primary health care: strategies for control of disease in the developing world. XIII. Acute bacterial meningitis.

  1984cited by this paper
• Selective primary health care: strategies for control of disease in the developing world. XI. Dengue.

  1984cited by this paper
• Meningococcal disease and season in sub-Saharan Africa.

  1984influential reference
• Epidemic group C meningococcal meningitis in Upper Volta, 1979.

  1983cited by this paper
• Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation.

  1982cited by this paper
• Immune Response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis.

  1977cited by this paper
• Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines.

  1977cited by this paper
• A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.

  1977cited by this paper
• Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.

  1977cited by this paper
• Meningococcal Disease

  1974cited by this paper
• Prevention of meningococcal disease by group C polysaccharide vaccine.

  1970cited by this paper
• HUMAN IMMUNITY TO THE MENINGOCOCCUS

  1969cited by this paper
• HUMAN IMMUNITY TO THE MENINGOCOCCUS

  1969cited by this paper
• Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments

  year unknowncited by this paper

• Meningococcal Conjugate and Protein-Based Vaccines

  2016cites this paper
• A Geo-Informatics Technique for the Management of Meningitis Epidemic Distributions in Northern Nigeria

  2015cites this paper
• The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines.

  2014cites this paper
• The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?

  2013cites this paper
• Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.

  2012cites this paper
• New frontiers in meningococcal vaccines

  2011cites this paper
• Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology.

  2010cites this paper
• Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa.

  2009cites this paper
• Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae.

  2008cites this paper
• Climate and Environmental Information and the Control of Epidemic Meningitis in Africa

  2008cites this paper
• Meningococcal vaccines.

  2007cites this paper
• Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.

  2007cites this paper
• The Meningitis Vaccine Project.

  2007cites this paper
• Risk mapping and early warning systems for the control of meningitis in Africa.

  2007cites this paper
• Index to JHPN Articles

  2007cites this paper
• Vaccine prevention of meningococcal disease: making slow progress.

  2006cites this paper
• Prospects for Vaccine Prevention of Meningococcal Infection

  2006cites this paper
• Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.

  2005cites this paper